Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry

BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation. In clinical studies, dupilumab reduced the risk of severe asthma exacerbations, and improved forced expiratory volume i...

Descripción completa

Detalles Bibliográficos
Autores principales: Gall, Rebecca, Jain, Neal, Soong, Weily, Settipane, Russell A., Xia, Changming, Zhang, Yi, Haselkorn, Tmirah, Jacob-Nara, Juby A., Siddiqui, Shahid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988992/
https://www.ncbi.nlm.nih.gov/pubmed/36626107
http://dx.doi.org/10.1007/s12325-022-02399-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988992/
https://www.ncbi.nlm.nih.gov/pubmed/36626107
http://dx.doi.org/10.1007/s12325-022-02399-5

Ejemplares similares